
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide (Wegovy) and liraglutide, are transforming the management of type 2 diabetes mellitus (T2DM) and obesity. Everyone is well-versed in their effects on blood sugar, weight, and the cardiovascular system.
One area of growing clinical interest is the impact of GLP-1 RAs on eye health, specifically their relationship with glaucoma, a progressive optic neuropathy that can lead to irreversible vision loss.
According to the National Health Service (NHS), glaucoma is a significant public health concern, with chronic open-angle glaucoma affecting approximately 480,000 people across the country.
Recent research supported by large-scale retrospective studies suggests that GLP-1 RAs are associated with a reduced risk of glaucoma incidence, particularly primary open-angle glaucoma (POAG), compared with other antidiabetic agents. This article provides a comprehensive, evidence-based analysis of the current state of knowledge regarding GLP-1 RAs and glaucoma risk.
GLP-1 RAs, also known as incretin mimetics, are a class of drugs that enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety, making them effective treatments for T2DM and obesity. Semaglutide, in particular, has gained widespread attention due to its efficacy in both glycaemic control and weight reduction.
Glaucoma is an umbrella term for a group of optic neuropathies characterised by progressive loss of retinal ganglion cells (RGCs) and corresponding visual field defects, frequently but not exclusively associated with elevated intraocular pressure (IOP). The most common subtype, primary open-angle glaucoma (POAG), is a leading cause of irreversible blindness worldwide. Diabetes is a well-recognised risk factor for glaucoma, likely due to shared pathways involving vascular dysregulation, oxidative stress, and neurodegeneration.
Several robust observational studies have investigated the association between GLP-1 RA use and glaucoma risk. Population-based registry analyses from Denmark and large US cohort studies consistently demonstrate a protective signal. Research, like a Danish nationwide case control study, found that patients with T2DM initiating GLP-1 RA therapy had a 19–29% lower risk of developing POAG compared to those prescribed other anti-diabetic agents. These findings further suggest that the magnitude of risk reduction increases with the duration of GLP-1 RA exposure; patients using these agents for more than three years experienced the most pronounced benefits.
Importantly, emerging data indicate that the glaucoma-protective effect of GLP-1 RAs may extend beyond patients with diabetes. Observational analyses in obese, non-diabetic individuals prescribed GLP-1 RAs for weight management also show a reduced risk of incident glaucoma.
This suggests the benefit may not solely be attributabled to improved glycaemic control and may instead reflect a direct neuroprotective action. While these findings are compelling, it is crucial to acknowledge the limitations inherent in observational research, including residual confounding and potential selection bias.
Nevertheless, the consistency and magnitude of the association, alongside plausible biological mechanisms, strengthen the case for a genuine effect.
The mechanisms underlying the glaucoma-protective effects of GLP-1 RAs are under active investigation. The following pathways are most frequently proposed:
Collectively, these mechanisms align with contemporary theories of glaucoma pathogenesis as a neurodegenerative disease with vascular and inflammatory components, not simply one of elevated IOP.
While the evidence for a glaucoma-protective effect is encouraging, clinicians should balance this against specific ocular safety considerations associated with GLP-1 RAs. These include the potential for diabetic retinopathy progression and the rare but serious risk of non-arteritic anterior ischemic optic neuropathy (NAION).
A paradox exists in the relationship among GLP-1 RAs, glycaemic control, and progression of diabetic retinopathy (DR). Long-term glycaemic improvement is unequivocally beneficial for retinopathy risk, yet rapid reductions in glycated haemoglobin (HbA1c), particularly greater than 2% over a short period, can transiently worsen pre-existing, advanced DR. This phenomenon was highlighted in the SUSTAIN-6 trial, where patients with advanced baseline DR who experienced rapid HbA1c declines on semaglutide had higher rates of retinopathy progression compared to controls.
Key clinical implications include:
This emphasises the need for careful patient selection and counselling, as well as integrated care between diabetologists, general practitioners, and ophthalmologists.
NAION is characterised by sudden, painless visual loss due to infarction of the optic nerve head in the absence of giant cell arteritis. While rare, several post-marketing reports and some large database studies suggest a possible increased risk of NAION associated with certain GLP-1 RAs, including semaglutide.
The proposed mechanism involves systemic fluctuations in blood pressure and glucose, which, when superimposed on a “disc at risk” (an anatomically crowded optic nerve head), may precipitate ischemic events. Patients with diabetes, hypertension, hyperlipidaemia, and established small vessel disease are particularly susceptible.
Clinical recommendations include:
The neuroprotective properties of GLP-1 RAs in glaucoma reflect a broader paradigm shift in the management of neurodegenerative diseases, emphasising multi-modal strategies that target not only acute injury but also the chronic processes underpinning neuronal loss. Lessons from preclinical and translational research in cerebral ischemia and stroke illuminate both the promise and challenges of neuroprotective therapy.
Amato and Arnold (2020) provided additional mechanistic clarity, modelling the activation of microglia and the balance between pro- and anti-inflammatory phenotypes (M1 and M2) in ischemic stroke. Their results suggest that early inhibition of M1 (pro-inflammatory) activation and support of M2 (anti-inflammatory) activation can shift the neuroinflammatory milieu towards tissue repair and recovery. By extension, GLP-1 RAs through their modulation of microglial activation may replicate these neuroprotective dynamics in the optic nerve, offering a biological rationale for the observed reduction in glaucoma risk.
Current research has examined a possible association between GLP-1 receptor agonist use and glaucoma-related outcomes, but the evidence remains limited and observational. Proposed neurobiological mechanisms have not been conclusively established, and no protective effect has been confirmed.
Existing literature highlights the importance of clinical awareness of ocular changes, particularly in people with diabetes, including transient changes in diabetic retinopathy and rare optic nerve events. Clinical decisions should continue to follow approved indications, individual patient factors, and established guidelines.
Further prospective and randomised studies are needed to clarify any relationship between GLP-1 receptor agonists and glaucoma, as well as their long-term ocular safety.